Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    

3SBIO INC. (ADR)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 729 M
EBIT 2017 1 101 M
Net income 2017 892 M
Debt 2017 1 646 M
Yield 2017 0,27%
Sales 2018 5 037 M
EBIT 2018 1 430 M
Net income 2018 1 180 M
Debt 2018 1 114 M
Yield 2018 0,32%
P/E ratio 2017 33,84
P/E ratio 2018 25,70
EV / Sales2017 8,52x
EV / Sales2018 6,20x
Capitalization 30 108 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
10/27Presentation
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
10/13 3SBIO : new product approved for clinical trials
09/18 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
09/14 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
09/04 3SBIO : forms joint venture to buy CDMO business
09/04 3SBIO : Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Develop..
09/04 3SBIO : Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therap..
09/04 ANNOUNCEMENT (1) MAJOR TRANSACTION A : Formation of joint venture and grant of p..
09/03 3SBIO : Accelerates Expansion of its Global Biologics Platform by Acquiring the ..
08/30 3SBIO : interim net up 37% to Rmb393m; no div
08/29 3SBIO : Notification of interim results announcement
More news
Sector news : Biopharmaceuticals
07:50aDJNOVARTIS : 3Q Net Profit Rises as New Drugs Offset Generic Competition
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 Smith & Nephew to buy Rotation Medical for up to $210 million
10/23DJEuropean Corporate Roundup for Monday
10/23DJDrug Makers Find 'Branded Generics' Are a Source for Growth
More sector news : Biopharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 11,4  CNY
Spread / Average Target -4,2%
EPS Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu CSO, President-Research & Development
Dong Mei Su Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)4 544
BIOGEN25.72%69 466
CSL LIMITED39.35%49 444
ALEXION PHARMACEUTICALS10.50%30 175
GRIFOLS SA27.99%17 705
BIOMARIN PHARMACEUTICAL4.37%15 154